By Paula Lorgelly, Braden Te Ao and Richard Edlin of
Photo:
Opinion - New Zealand's drug-buying agency Pharmac is currently consulting on a change to how it manages its waiting list for medicines.
This represents one of the stages of Pharmac's "reset" through which the agency seeks to become more outward-focused and transparent.
The consultation focuses on how Pharmac manages its Options for Investment list - essentially a wish list of what Pharmac would like to fund if it had the budget.
For medicines that have been at the bottom of the list for more than two years, Pharmac wants to decline 20 percent if there are more than 100 applications on the overall list, or 10 percent if there are fewer than 100.
A useful analogy is to
Continue Reading on RNZ
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.